Primer: Medtide (3880 HK) - Aug 2026
Pure-Play Peptide CRDMO Positioned for Sector Tailwinds: Medtide is a specialized Contract Research, Development, and Manufacturing...
105 Views
Medtide (泰德医药) IPO Trading Update
Medtide raises $65.5m in global offering, set to list on Hong Kong Stock Exchange June 30th. We provide an update prior to trading debut on Monday.
433 Views
Medtide (泰德医药) IPO: Aggressive Valuation
Chinese CDMO Medtide launches IPO in Hong Kong to raise up to US$66m. We think its valuation and guidance are aggressive despite being a niche...
436 Views
Medtide (泰德医药) Pre-IPO: Mind the CG Risk
Chinese peptide-focused CDMO Medtide plans to raise $100m in Hong Kong listing with deal sponsors MS and CITIC. We look at the company's...
530 Views
Pre-IPO Medtide (PHIP Updates) - Some Points Worth the Attention
GLP-1 sales growth is at a turning point with market size potentially lower than expected, impacting growth outlook for peptide CXOs like Medtide....
474 Views